KILITCH DRUGS (INDIA) LTD.

Kilitch Drugs India Ltd announced the resignation of Mr. Venkita Subramanian Rajan from his position as Non-Executive Independent Director, effective immediately. The resignation is attributed to pre-occupation and other personal commitments. Consequently, Mr. Rajan will also step down from his roles as Chairman and/or Member of the Audit Committee, Nomination and Remuneration Committee, and Stakeholder Relationship Committee. The company has filed the necessary disclosures with the stock exchanges.

Kilitch Drugs India Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code. The window will be shut from October 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending September 30, 2026. The exact date for the Board of Directors' meeting to approve these results will be communicated later.

Kilitch Drugs India Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, concerning its Right Issue of equity shares amounting to ₹49.92 crore. The report, issued by Infomerics Valuation and Rating Limited, confirms no deviation from the objects for which the issue proceeds were earmarked. This disclosure aligns with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The company will also host this report on its website.

Kilitch Drugs India Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved both standalone and consolidated results. The company reported total income and incurred expenses, leading to profit before tax. The results were accompanied by a limited review report from the auditors. The board meeting where these results were approved commenced at 16:30 hours and concluded at 20:40 hours on August 13, 2026.

Kilitch Drugs India Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results during a meeting held on August 13, 2026. The company operates predominantly in the Pharmaceuticals sector, with no separate reporting segments as per Ind-AS108. The results were reviewed by the Audit Committee and approved by the Board.

Kilitch Drugs India Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. In line with SEBI regulations and the company's code of conduct for preventing insider trading, the trading window has been closed from July 1, 2026, and will reopen 48 hours after the disclosure of these financial results to the stock exchanges.

Kilitch Drugs India Ltd has issued physical intimation letters to shareholders whose email addresses are not registered. These letters provide a weblink to access the Annual Report for FY 2025-26 and the Notice of AGM, in compliance with SEBI regulations. The company is also reminding shareholders to update KYC details and dematerialize physical securities as per recent SEBI circulars. The 34th AGM is scheduled for August 27, 2026, via Video Conferencing.

Kilitch Drugs India Ltd has submitted its Annual Report for the financial year 2025-26 and the notice for its 34th Annual General Meeting (AGM). The AGM is scheduled for Thursday, August 27, 2026, at 9:00 am IST, to be conducted via Video Conferencing or Other Audio Visual Means. Both the Annual Report and the AGM notice are available on the company's website, www.kilitch.com. The filing is in accordance with SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 and relevant MCA/SEBI circulars. The company highlights its global reach, manufacturing capabilities, and commitment to quality and innovation.

Kilitch Drugs India Ltd has announced its 34th Annual General Meeting (AGM) will be held on Thursday, August 27, 2026, at 9:00 am IST. The meeting will be conducted exclusively through Video Conferencing or Other Audio Visual Means. Key agenda items include the adoption of audited standalone and consolidated financial statements for the year ended March 31, 2026, the re-appointment of Mr. Mukund P. Mehta as a director, approval of performance-linked incentives for executive directors, and ratification of remuneration to the Cost Auditor. The notice for the AGM, along with detailed instructions for remote e-voting and e-voting during the meeting, has been dispatched to members. The cut-off date for entitlement to vote is August 20, 2026, with remote e-voting commencing on August 24 and concluding on August 26, 2026.

Kilitch Drugs India Ltd announced that its Board of Directors met on July 28, 2026. The board approved the notice for the 34th Annual General Meeting (AGM) to be held on August 27, 2026, via video conferencing. They also approved the Directors' Report, Corporate Governance Report, and related annexures for the financial year ended March 31, 2026. Mr. Deep Shukla was appointed as the scrutinizer for the AGM voting process. The company also announced the closure of its Register of Members and Share Transfer Books from August 20 to August 27, 2026, for the AGM. Additionally, M/s Arvind Kumar & Co. were re-appointed as Cost Auditors for the financial year 2026-27.